Metraipolis › archive › dc_2446ccfb9705

Favorable response to third-generation TKI furmonertinib in a patient with early-stage non-small cell lung cancer harboring rare compound EGFR mutations: Exon… — Europe PMC PMID:41626155

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41626155
DOI
10.3389/fonc.2025.1714432
License (as archived)
solo-consultazione
Archived
2026-11-06T18:09:44.529Z
SHA-256 of the archived text
858509913f6d50f1e59c211b4dc75f7d8fa3372f64f77e9f31eebb7c5fdaa084
Stable URL of this page
https://metraipolis.com/documento/dc_2446ccfb9705

How to cite

Favorable response to third-generation TKI furmonertinib in a patient with early-stage non-small cell lung cancer harboring rare compound EGFR mutations: Exon… — Europe PMC PMID:41626155 — Europe PMC (en), https://europepmc.org/article/MED/41626155 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2446ccfb9705 (Metraipolis archive dc_2446ccfb9705, sha256 858509913f6d50f1e59c211b4dc75f7d8fa3372f64f77e9f31eebb7c5fdaa084)
BibTeX
@misc{dc2446ccfb9705,
  title = {Favorable response to third-generation TKI furmonertinib in a patient with early-stage non-small cell lung cancer harboring rare compound EGFR mutations: Exon… — Europe PMC PMID:41626155},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41626155},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2446ccfb9705; sha256 858509913f6d50f1e59c211b4dc75f7d8fa3372f64f77e9f31eebb7c5fdaa084},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41626155. Agents can read the archived copy with the MCP tool read_document.